Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 13/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075874 | 0.92 | GRM4 (0.53) | GRM4PTK6EGFRERBB2EPHA2 | |
| SCHEMBL17075835 | 0.89 | EGFR (0.62) | EGFRERBB2GAK | |
| SCHEMBL17075851 | 0.86 | EGFR (0.49) | GRM4PTK6EGFRERBB2EPHA2 | |
| Hydrochloric Acid SCHEMBL8809228 | 0.82 | EGFR (0.59) | EGFRERBB2GAK | |
| SCHEMBL17075870 | 0.81 | EGFR (0.62) | EGFRERBB2GAK | |
| SCHEMBL17075852 | 0.81 | ALK (0.60) | GRM4PTK6EGFRERBB2GAK | |
| SCHEMBL17075829 | 0.80 | EGFR (0.49) | GRM4PTK6EGFRERBB2EPHA2 | |
| SCHEMBL17075809 | 0.79 | PTK6 (0.60) | GRM4PTK6EGFRERBB2GAK | |
| SCHEMBL17083357 | 0.78 | EGFR (0.52) | GRM4PTK6EGFRERBB2GAK | |
| SCHEMBL17075819 | 0.76 | EGFR (0.60) | EGFRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | TPP1, MKI67, PIGO | GRM4 3364/4885PTK6 1406/4885EGFR 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.